Sermorelin & GHRP-2 Blend – 10MG – High-Purity Research Peptide
Sermorelin & GHRP-2 Blend – 10MG is a research peptide combination containing 5mg of Sermorelin and 5mg of GHRP-2. Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), while GHRP-2 is a synthetic growth hormone secretagogue studied in relation to the ghrelin receptor system.
The combination is of interest in laboratory research because the two peptides interact with distinct signalling pathways involved in pituitary growth hormone regulation.
Core Peptides lists this product as a 10mg lyophilised powder with a stated purity of >99%. The product is intended for qualified research, laboratory and analytical applications only and is not intended for human or animal consumption.
What Is Sermorelin & GHRP-2 Blend?
The Sermorelin & GHRP-2 Blend combines two synthetic peptides that have been investigated for their effects on growth hormone signalling. Sermorelin represents the first 29 amino acids of endogenous GHRH and is commonly described as GHRH(1-29)-NH2. GHRP-2, also known as pralmorelin, is a synthetic hexapeptide belonging to the growth hormone-releasing peptide family.
Although both peptides are associated with growth hormone research, they are structurally and mechanistically distinct. Sermorelin is primarily studied through the GHRH receptor, whereas GHRP-2 is associated with the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor.
This difference makes the blend particularly relevant to researchers studying how separate receptor systems can converge within pituitary somatotroph cells and influence growth hormone secretion.
Sermorelin & GHRP-2 Blend – 10MG Product Specifications
| Specification | Details |
|---|---|
| Product Name | Sermorelin & GHRP-2 Blend |
| Total Quantity | 10mg |
| Sermorelin | 5mg |
| GHRP-2 | 5mg |
| Ratio | 1:1 |
| Form | Lyophilised powder |
| Listed Purity | >99% |
| Sermorelin Alternative Name | GRF 1-29 NH2 |
| GHRP-2 Alternative Name | Pralmorelin |
| SKU | Sermorelin-GHRP-2-10mg |
| Intended Use | Research, laboratory and analytical purposes |
Core Peptides currently identifies the blend as containing 5mg Sermorelin and 5mg GHRP-2 in a lyophilised powder format, with a listed purity of greater than 99%.
What Is Sermorelin?
Sermorelin is a synthetic 29-amino-acid analogue of human growth hormone-releasing hormone. It corresponds to the biologically active N-terminal region of GHRH and is commonly identified as GHRH(1-29)-amide.
Research has investigated Sermorelin because its structure retains important features involved in interaction with GHRH receptors on pituitary somatotroph cells. Activation of these receptors is associated with intracellular signalling pathways that regulate growth hormone synthesis and secretion.
For laboratory researchers, Sermorelin provides a defined model for investigating the GHRH side of the growth hormone regulatory system.
What Is GHRP-2?
GHRP-2, also known as pralmorelin, is a synthetic hexapeptide belonging to the growth hormone-releasing peptide family. Research has investigated GHRP-2 primarily in relation to growth hormone secretagogue receptors and pituitary hormone secretion.
GHRP-2 is structurally different from Sermorelin and does not simply reproduce the GHRH sequence. Its research profile centres on the GHS-R1a receptor, a G-protein-coupled receptor that is also associated with the biological actions of ghrelin.
This distinct receptor profile is one reason GHRP-2 is frequently investigated alongside GHRH analogues in studies of growth hormone regulation.
How Does the Sermorelin & GHRP-2 Blend Work in Research?
The principal research interest in this combination comes from the fact that the two peptides are associated with different receptor systems.
Sermorelin is investigated primarily through the GHRH receptor on pituitary somatotroph cells. GHRP-2, by contrast, is associated with GHS-R1a. Both signalling systems can ultimately influence the machinery responsible for growth hormone synthesis and release.
At the cellular level, GHRH receptor signalling can involve G-protein activation, adenylate cyclase and cyclic AMP. GHS-R1a signalling has been studied in connection with pathways involving phospholipase C, intracellular calcium and protein kinase C.
Researchers therefore use combinations such as Sermorelin and GHRP-2 to investigate whether simultaneous stimulation of these distinct pathways produces different growth hormone responses compared with activation of either pathway alone.
Sermorelin & GHRP-2 and Growth Hormone Research
Growth hormone is secreted by specialised pituitary cells known as somatotrophs. Its release is regulated by multiple hypothalamic and peripheral signals, including GHRH and ghrelin-related pathways.
Research cited by Core Peptides has examined the effects of GHRH analogues and GHRP-2 on pituitary growth hormone secretion. These studies have reported increases in GH output under specific experimental conditions.
The combination is therefore useful as an experimental model for examining how different secretagogue pathways influence the amplitude, timing and pattern of GH secretion.
Research Into Potential Synergy
One of the most important research questions surrounding this combination is whether simultaneous activation of the GHRH and GHS-R1a pathways can produce a response greater than either pathway alone.
Research involving GHRP-2 and GHRH has reported substantially amplified growth hormone responses when both secretagogues were present in experimental systems. Core Peptides cites studies in which combined exposure produced greater integrated GH output than GHRP-2 alone.
Because Sermorelin is a GHRH analogue, this provides a mechanistic rationale for investigating Sermorelin and GHRP-2 together. However, the existence of synergistic findings in particular experimental models does not establish that the same response will occur with every formulation, concentration or biological system.
Sermorelin & GHRP-2 and IGF-1 Research
Insulin-like growth factor-1 (IGF-1) is an important downstream component of the growth hormone axis. Growth hormone can influence IGF-1 production in several tissues, particularly the liver, making IGF-1 an important marker in research involving GH signalling.
Studies cited by Core Peptides have examined IGF-1 alongside GH responses following exposure to Sermorelin or GHRP-2. Some experimental work has reported changes in circulating IGF-1 following prolonged peptide exposure.
Researchers may therefore measure both GH and IGF-1 when investigating how secretagogue combinations influence the broader somatotropic axis.
Sermorelin & GHRP-2 Pituitary Cell Research
Pituitary somatotroph cells provide a particularly useful model for studying the blend. These cells express receptors associated with GHRH and growth hormone secretagogue signalling.
In laboratory studies, Sermorelin can be used to examine GHRH receptor-mediated signalling, while GHRP-2 can be used to investigate GHS-R1a-mediated signalling. Measuring downstream responses can help researchers understand how the two pathways interact at the cellular level.
Potential endpoints include:
- Growth hormone secretion.
- Intracellular cyclic AMP.
- Intracellular calcium mobilisation.
- Protein kinase signalling.
- Gene expression related to GH synthesis.
- Changes in secretory-pulse characteristics.
Sermorelin & GHRP-2 Receptor Signalling
GHRH Receptor Pathway
Sermorelin interacts with the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Activation of this receptor has been associated with G-protein-mediated stimulation of adenylate cyclase and increased cyclic AMP signalling.
GHS-R1a Pathway
GHRP-2 is associated with GHS-R1a, a seven-transmembrane G-protein-coupled receptor also known as the growth hormone secretagogue receptor. Research has examined downstream signalling involving phospholipase C, calcium mobilisation and protein kinase C.
Converging Signals
Although the receptor systems are distinct, their downstream effects can converge within pituitary somatotroph cells. This provides a useful framework for investigating how multiple extracellular signals regulate growth hormone synthesis and secretion.
Potential Research Applications
Qualified laboratories may investigate Sermorelin & GHRP-2 Blend – 10MG across several areas of peptide and endocrine research, including:
- GHRH receptor signalling.
- GHS-R1a receptor research.
- Pituitary somatotroph biology.
- Growth hormone secretion studies.
- GH pulse-pattern research.
- IGF-1 pathway investigations.
- cAMP signalling studies.
- Intracellular calcium research.
- Protein kinase C signalling.
- Receptor cross-talk studies.
- Structure–activity relationship research.
- Comparative secretagogue studies.
- Endocrine physiology research.
Research Interest in Dual-Pathway Activation
The combination of Sermorelin and GHRP-2 is particularly relevant to researchers interested in dual-pathway activation. Rather than studying a single receptor system in isolation, researchers can investigate the effects of simultaneously engaging GHRH and growth hormone secretagogue pathways.
Research discussed by Core Peptides suggests that combined GHRH and GHRP signalling can produce a stronger GH secretory response than some individual treatments in experimental models.
This research concept can be explored through controlled cell-based experiments, receptor assays and endocrine models where the concentration, timing and biological endpoints are carefully defined.
Sermorelin & GHRP-2 Chemical Information
| Property | Sermorelin | GHRP-2 |
|---|---|---|
| Common Name | Sermorelin | GHRP-2 |
| Alternative Name | GRF 1-29 NH2 | Pralmorelin |
| Peptide Type | GHRH analogue | Growth hormone secretagogue peptide |
| Sequence Length | 29 amino acids | 6 amino acids |
| Quantity in Blend | 5mg | 5mg |
| Blend Ratio | 1:1 | |
| Physical Form | Lyophilised powder | |
Core Peptides identifies the product as a 1:1 blend containing 5mg Sermorelin and 5mg GHRP-2. It lists Sermorelin as GRF 1-29 NH2 and GHRP-2 as pralmorelin.
Why Choose Sermorelin & GHRP-2 Blend – 10MG?
Sermorelin & GHRP-2 Blend – 10MG provides researchers with two distinct peptide signalling systems in a single research format.
- 10mg total peptide: Contains 5mg Sermorelin and 5mg GHRP-2.
- 1:1 composition: Provides an equal quantity of each research peptide.
- >99% listed purity: Core Peptides lists the blend at greater than 99% purity.
- Lyophilised presentation: Supplied as a dry peptide preparation.
- Two distinct receptor systems: Enables research into GHRH and GHS-R1a signalling within the same experimental framework.
- Established research background: Both peptides have been investigated extensively in growth hormone and endocrine research.
Analytical Testing and Research Quality
Laboratories working with peptide materials may use analytical methods to confirm molecular identity and evaluate purity. Depending on the research requirements, relevant techniques can include:
- High-performance liquid chromatography (HPLC) for chromatographic purity analysis.
- Mass spectrometry for molecular-mass and identity confirmation.
- Peptide mapping for structural characterisation.
- Receptor-binding assays for investigating peptide–receptor interactions.
- Cell-based assays for examining biological responses.
- Hormone assays for measuring experimental GH or IGF-1 responses.
Researchers should consult the applicable batch-specific Certificate of Analysis and technical documentation before beginning laboratory work.
Laboratory Handling and Storage
Sermorelin & GHRP-2 Blend – 10MG is supplied as a lyophilised powder. Researchers should follow the supplier’s current storage guidance together with their institution’s validated procedures for peptide handling.
- Keep the product in its original labelled container.
- Protect the lyophilised material from unnecessary exposure to moisture.
- Follow the supplier’s current recommended storage conditions.
- Minimise unnecessary temperature fluctuations.
- Use suitable laboratory protective equipment.
- Follow institutional procedures for handling and disposal.
- Review batch-specific analytical documentation before experimental use.
Storage requirements can vary according to formulation, packaging and experimental protocol. Always follow the current technical documentation supplied with the product.
Frequently Asked Questions About Sermorelin & GHRP-2 Blend – 10MG
What is Sermorelin & GHRP-2 Blend?
It is a research peptide blend containing equal quantities of Sermorelin and GHRP-2. The Core Peptides formulation contains 5mg Sermorelin and 5mg GHRP-2, for a total of 10mg.
What is the ratio of Sermorelin to GHRP-2?
The blend uses a 1:1 ratio, with 5mg of each peptide.
What is Sermorelin?
Sermorelin is a synthetic 29-amino-acid analogue of GHRH. It is primarily researched for its interaction with GHRH receptors and its role in studies of pituitary growth hormone signalling.
What is GHRP-2?
GHRP-2 is a synthetic hexapeptide, also known as pralmorelin. It has been investigated as a growth hormone secretagogue and in relation to the GHS-R1a receptor.
Why are Sermorelin and GHRP-2 studied together?
The two peptides are associated with different receptor systems involved in growth hormone regulation. Researchers can therefore investigate how simultaneous GHRH receptor and GHS-R1a signalling affects pituitary somatotroph responses.
What is the purity of the blend?
Core Peptides currently lists the Sermorelin & GHRP-2 Blend with a purity of >99%.
What form is the product supplied in?
The product is supplied as a lyophilised powder.
What is the research focus of Sermorelin?
Sermorelin is primarily researched in relation to GHRH receptors, pituitary somatotroph cells, growth hormone secretion and the broader GH/IGF-1 axis.
What is the research focus of GHRP-2?
GHRP-2 is primarily researched in relation to growth hormone secretagogue receptor signalling, pituitary GH secretion and intracellular pathways associated with GHS-R1a activation.
Does the blend prove that Sermorelin and GHRP-2 are synergistic?
No. Research has reported potentially enhanced GH responses when GHRH and GHRP pathways are activated together in particular experimental systems, but this does not establish a universal synergistic effect for every formulation, concentration or biological model.
Is Sermorelin & GHRP-2 Blend intended for human use?
No. The Core Peptides product is marketed for research, laboratory and analytical purposes only and is not intended for human or animal consumption.
Can this product be used for bodybuilding or performance enhancement?
This product should not be promoted or used for bodybuilding, athletic performance or self-administration. It is supplied as a research material and should only be handled by appropriately qualified personnel within suitable laboratory settings.
Sermorelin & GHRP-2 Blend – 10MG Research Summary
Sermorelin & GHRP-2 Blend – 10MG combines two experimentally important peptides associated with growth hormone regulation. The formulation contains 5mg Sermorelin and 5mg GHRP-2 in a 1:1 ratio and is supplied as a lyophilised research material with a listed purity greater than 99%.
Sermorelin represents a GHRH analogue that is primarily investigated through the GHRH receptor, while GHRP-2 is associated with the GHS-R1a receptor. Their distinct signalling routes provide a useful experimental framework for studying pituitary somatotroph activity, growth hormone secretion, receptor cross-talk and the GH/IGF-1 axis.
Research involving GHRH and GHRP systems has reported potentially enhanced GH responses when both pathways are activated under specific experimental conditions. Nevertheless, these findings should be interpreted according to the study design, biological model and experimental parameters rather than treated as established therapeutic outcomes.
Research-Use Disclaimer
Sermorelin & GHRP-2 Blend – 10MG is intended solely for qualified research, laboratory, analytical and in-vitro experimental purposes. It is not intended for human or veterinary consumption, self-administration, diagnosis, treatment, cure or prevention of any disease.
References to growth hormone, IGF-1, endocrine signalling, body composition or other biological effects describe areas of scientific investigation and should not be interpreted as established clinical benefits or medical advice.
Researchers should review the applicable Certificate of Analysis, product documentation, safety information and relevant legislation before working with this material. Handling, storage and disposal should be performed by appropriately trained personnel using suitable laboratory procedures.
For research use only. Human and animal consumption prohibited.
Product specifications and availability should be verified against the current supplier listing before publication or purchase.
Be the first to review “Sermorelin & GHRP-2 Blend – 10MG”
Related products
Peptides for Sale
Peptides for Sale
Peptides for Sale
Peptides for Sale
Peptides for Sale
Peptides for Sale
Peptides for Sale
Peptides for Sale
Reviews
There are no reviews yet.